| Title |
Metformin Use Among Individuals at Risk for Type 2 Diabetes
|
|---|---|
| Published in |
Current Diabetes Reports, March 2012
|
| DOI | 10.1007/s11892-012-0263-x |
| Pubmed ID | |
| Authors |
Lewis H. Kuller |
| Abstract |
Excess total and cardiovascular morbidity and mortality remain very high among those with type 2 diabetes versus those without diabetes. Clinical trials to lower blood glucose have been disappointing probably because the participants were too late in the natural history of diabetes and already had extensive vascular disease. Insulin resistance measured simply by elevated fasting blood insulin is an early marker of β-cell stress and peripheral insulin resistance. Metformin will prevent development of diabetes among patients with impaired fasting glucose but only for the short term. Metformin reduces risk of coronary heart disease. The drug is safe, low cost, and may also prevent cancer. The combination of diet and exercise followed by metformin in the early phase of "insulin resistance" may reduce or delay both atherosclerosis and arteriosclerosis complications associated with diabetes. Preventive therapy must begin much earlier than before clinical diagnosis of diabetes and aim to initially lower blood insulin levels or insulin resistance. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Germany | 1 | 2% |
| Brazil | 1 | 2% |
| Unknown | 63 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 11 | 17% |
| Researcher | 8 | 12% |
| Student > Bachelor | 8 | 12% |
| Student > Ph. D. Student | 8 | 12% |
| Other | 4 | 6% |
| Other | 11 | 17% |
| Unknown | 15 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 26 | 40% |
| Nursing and Health Professions | 7 | 11% |
| Agricultural and Biological Sciences | 3 | 5% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Sports and Recreations | 3 | 5% |
| Other | 7 | 11% |
| Unknown | 16 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 March 2012.
All research outputs
#20,156,138
of 22,663,969 outputs
Outputs from Current Diabetes Reports
#920
of 1,005 outputs
Outputs of similar age
#141,559
of 156,267 outputs
Outputs of similar age from Current Diabetes Reports
#9
of 9 outputs
Altmetric has tracked 22,663,969 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,005 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 156,267 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one.